(IN BRIEF) The European Society of Cardiology’s new Clinical Consensus Statement, published on 3 June 2025 in the European Heart Journal, positions vaccination as a core component of cardiovascular prevention. It reviews evidence that infections such as influenza, pneumonia, SARS-CoV-2, … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, News, Non Profit, Science, Technology
Tagged ACC/AHA guidelines, ACVC, cardiovascular prevention, EAPC, ESC Clinical Consensus Statement, European Heart Journal, European Society of Cardiology, heart failure, HFA, influenza, major adverse cardiovascular events, myocarditis, pneumonia, preventive cardiology, respiratory syncytial virus, SARS-CoV-2, Thomas F. Lüscher, vaccination
(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged FDA approval, influenza strains, Nadia Aelbrecht, Outpatient Respiratory Diagnostics, QIAGEN, QIAstat-Dx Mini Panel, Rapid Results, safety, SARS-CoV-2
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure that the healthcare community has access to timely, reliable and accurate COVID-19 PCR testing … Read the full press release
Le test qualitatif cobas SARS-CoV-2 est l’un des premiers tests PCR COVID-19 effectués sur une plateforme automatisée à haut débit à recevoir l’autorisation FDA 510(k). Cette autorisation de la FDA garantira que la communauté des soins de santé a accès … Read the full press release
(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — Na luta contra o vírus SARS-CoV-2, um grande número de empresas farmacêuticas está em busca de novas abordagens para combater a pandemia. Além das vacinas, estão a ser feitos esforços intensivos … Read the full press release
Posted in Austria, Germany, Healthcare, Hungary, News, Pharma & Biotech, Portugal, Science
Tagged anti-COVID, anti-histamínico, anti-histamínico azelastina, anti-SARS-CoV-2, antivirais, azelastina, CEBINA, COVID-19, medicamento antialérgico, Professor Ferenc Jakab, Professor Robert Konrat, SARS-CoV-2, Sophie Zettl, Spray Nasal Pollival, sprays nasais, terapia antialérgica, URSAPHARM Arzneimittel
(PRESS RELEASE) SAARBRÜCKEN / VIENA, 17-Feb-2021 — /EuropaWire/ — En la lucha contra el virus SARS-CoV-2, una gran cantidad de empresas farmacéuticas están buscando nuevos enfoques para combatir la pandemia. Además de las vacunas, las iniciativas exhaustivas de investigación y … Read the full press release
Posted in Austria, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science, Spain
Tagged aerosoles nasales, anti-SARS-CoV-2, antihistamínico azelastine, azelastine, biotecnología, CEBINA, colaboración, COVID-19 medication, COVID-19 treatment, fármaco antihistamínico clorhidrato de azelastina, medicamento antialérgico Pollival, nuevas terapias anti-COVID, pandemia, profesor Dr.Ferenc Jakab, profesor Dr.Robert Konrat, readaptación de medicamentos, SARS-CoV-2, Sophie Zettl, URSAPHARM Arzneimittel
(PRESS RELEASE) SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EuropaWire/ — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts … Read the full press release
Posted in Austria, Germany, Healthcare, Hungary, News, Pharma & Biotech, Science
Tagged anti-allergic medication Pollival, anti-COVID therapeutics, antihistamine drug, antiviral properties, azelastine, azelastine hydrochloride, CEBINA GmbH, Central European Biotech Incubator and Accelerator, clinical trial, COVID-19, COVID-19 medication, Covid-19 pandemic, COVID-19 treatment, nasal spray, ophthalmology, Pollival, Prof Dr Robert Konrat, Prof Dr. Ferenc Jakab, re-purpose drugs, SARS-CoV-2, Sophie Zettl, University of Pécs, University of Vienna, URSAPHARM Arzneimittel GmbH, viral spread
(PRESS RELEASE) LIVERPOOL, 25-Jan-2021 — /EuropaWire/ — University of Liverpool announces that its has joined a consortium to develop new anti-viral technology that will limit the transmission of SARS-CoV-2 (Covid-19) from touching contaminated surfaces in areas such as hospitals, train … Read the full press release
Posted in Education, Healthcare, News, Science, Technology, United Kingdom
Tagged Alder Hey, anti-viral coatings, anti-viral surfaces, anti-viral technology, anti-viral touch screen coating, Antimicrobial Surfaces, Biaccon Ltd, BIRA, COVID transmission, COVID-19, Dr Dermot Monaghan MD, Gencoa Ltd, Innovate UK grants, Liverpool School of Tropical Medicine, Northern Rail, Peter Rutter MD, point-of-sale cleansing system, Professor Rasmita Raval, SARS-CoV-2, scientists, University of Liverpool, University of Liverpool’s Open Innovation Hub, viral transmission
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating COVID-19 in addition to other diseases for which no therapeutic solutions are available (PRESS RELEASE) PARIS, 30-Nov-2020 — /EuropaWire/ — … Read the full press release
Posted in Banks, European Union, Financial, France, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Small Business
Tagged 3CL protease, AB Science SA, Alain Moussy, Ambroise Fayolle, anti-inflammatory, antiviral, chemotherapy, COVID-19, COVID-19 treatment, EIB, European Commission, European Fund for Strategic Investments, European Investment Bank, European Union, financing, health crisis, Horizon 2020, immunotherapeutic, inflammatory disease, innovationm, InnovFin, investments, kinase inhibitors, kinases, loan, macrophages, masitinib, microglia, neurological diseases, oncology, PKIs, RESEARCH, SARS-CoV-2, tyrosine kinase inhibitor
The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged Anti-SARS-CoV-2 S, antibodies, antibody test, COVID-19, Elecsys Anti-SARS-CoV-2 S test, Elecsys Anti-SARS-CoV-2 serology test, Elecsys®, Emergency Use Authorisation, EUA, FDA, Roche, SARS-CoV-2, SARS-CoV-2 vaccine, Thomas Schinecker, vaccines
(PRESS RELEASE) LONDON/ PARIS, 8-Jul-2020 — /EuropaWire/ — Digital transformation leader Atos has announced it will launch global HPC, AI & Quantum Life Sciences Centre of Excellence in agreement with Wellcome Genome Campus in Cambridgeshire, UK. The Centre will provide … Read the full press release
Posted in Artificial Intelligence (AI), Education, France, News, Science, Technology, United Kingdom
Tagged AI, AI & Quantum Life Sciences Centre of Excellence, AI & Quantum technologies, Atos, Atos Quantum Learning Machine, BullSequana X supercomputers, COVID-19, Cybersecurity, digital transformation, Dr Jo Mills, Dr Julia Wilson, High Performance Computing, HPC, Laura Fau, Pierre BARNABÉ, quantum, SARS-CoV-2, Wellcome Genome Campus
(PRESS RELEASE) GHENT, 12-May-2020 — /EuropaWire/ — Fujirebio Europe, part of Japanese in vitro diagnostics (IVD) testing leader Fujirebio, has just announced the product it distributes across Europe the iAMP® COVID-19 Detection kit from its partner Atila Biosystems, Inc. of … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?